- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02860858
Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)
October 21, 2020 updated by: Rajavithi Hospital
Objective: To evaluate the efficacy of intravitreal aflibercept injection on visual acuity in patients with symptomatic macular PCV.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bangkok, Thailand, 10400
- Rajavithi Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or Female >/= 18 years
- Confirmed diagnosis of symptomatic macular PCV in the study eye defined by: - Active macular polypoidal lesions shown by ICGA and - Presence of serosanguinous maculopathy
- BCVA letter score between 78-24 using ETDRS visual acuity chart measured at 4 meters
Exclusion Criteria:
- Previous treatment with systemic anti-VEGF drugs within 6 months prior to Baseline (e.g., sorafenib [Nexavar®], sunitinib [Sutent®], bevacizumab [Avastin®])
Study eye:
- Active ocular inflammation or infection (ocular or periocular)
- Uncontrolled intraocular hypertension or glaucoma (IOP> 30 mmPIg) despite treatment with anti-glaucoma medication
- Predominantly-scarred PCV lesions
- Ocular disorders in the study eye (e.g. cataract, retinal vascular occlusion, diabetic retinopathy) that, in the opinion of the investigator may confound interpretation of study results or compromise VA or require medical or surgical intervention during the study period
- Prior treatment with verteporfin PDT, external-beam radiation, subfoveal or extrafoveal focal laser photocoagulation, submacular surgery, or transpupillary thermotherapy
- Prior treatment with any anti-VEGF compound or any investigational treatment
- Treatment with intravitreal or subtenon corticosteroid injection or device implantation within 90 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aflibercept
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Best corrected visual acuity (BCVA)
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 30, 2016
Primary Completion (Actual)
August 30, 2018
Study Completion (Actual)
December 31, 2018
Study Registration Dates
First Submitted
July 4, 2016
First Submitted That Met QC Criteria
August 8, 2016
First Posted (Estimate)
August 9, 2016
Study Record Updates
Last Update Posted (Actual)
October 23, 2020
Last Update Submitted That Met QC Criteria
October 21, 2020
Last Verified
May 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18265_CREC032/59BPs
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Symtomatic Macular Polypoidal Choroidal Vasculopathy
-
Novartis PharmaceuticalsRecruitingMacular Polypoidal Choroidal Vasculopathy (PCV)Korea, Republic of
-
Novartis PharmaceuticalsCompletedAge-related Macular Degeneration | Polypoidal Choroidal VasculopathyJapan, Taiwan, Hong Kong, Singapore, Thailand, Korea, Republic of, Malaysia
-
Singapore National Eye CentreBayerCompletedAge Related Macular Degeneration | Polypoidal Choroidal VasculopathySingapore
-
Pusan National University HospitalBayerCompletedPolypoidal Choroidal Vasculopathy | Exudative Age-related Macular DegenerationKorea, Republic of
-
Ophthotech CorporationCompletedIdiopathic Polypoidal Choroidal VasculopathyUnited States
-
Ophthotech CorporationWithdrawnIdiopathic Polypoidal Choroidal VasculopathyUnited States
-
Peking Union Medical College HospitalBayerRecruitingPolypoidal Choroidal VasculopathyChina
-
Federico II UniversityCompleted
-
Sun Yat-sen UniversityCompletedPolypoidal Choroidal VasculopathyChina
-
Nihon UniversityCompletedPolypoidal Choroidal VasculopathyJapan
Clinical Trials on Intravitreous aflibercept injection
-
Association for Innovation and Biomedical Research...CompletedDiabetes Mellitus Type II | Diabetes Mellitus Type I | High Risk Proliferative Diabetic RetinopathyPortugal
-
Beijing Tongren HospitalUnknownMacular DegenerationChina
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); National Institutes of Health (NIH); Regeneron...CompletedProliferative Diabetic Retinopathy | Vitreous HemorrhageUnited States, Canada
-
Indonesia UniversityBayerCompletedDiabetic Retinopathy | Diabetic Macular Edema | Clinically Significant Macular EdemaIndonesia
-
Jaeb Center for Health ResearchCompletedDiabetic Macular EdemaUnited States
-
Kim's Eye HospitalBayerRecruitingRetinal Angiomatous ProliferationKorea, Republic of
-
Instituto de Olhos de GoianiaUnknownChoroidal Retinal NeovascularizationBrazil
-
Medical College of WisconsinUniversity of Wisconsin, MilwaukeeCompletedDiabetic RetinopathyUnited States
-
Regeneron PharmaceuticalsCompletedNonproliferative Diabetic RetinopathyUnited States, Germany, Hungary, Japan, Puerto Rico, United Kingdom
-
Regeneron PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationUnited States